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Abstract
Objective: Transdermal estradiol patches are primarily designed for adult women. No 
low-dose patches are licensed for pubertal induction in hypogonadal girls. Low doses can 
be achieved by cutting a matrix patch into smaller pieces. However, the manufacturers 
do not guarantee stability or utility of cut estradiol patches. The aim of the study was to 
assess 1-month stability of cut estradiol patches from four different manufacturers in 
the laboratory at room temperature (+21°C) and at an elevated temperature (+35°C).
Design and methods: Estraderm MX 50 µg, Systen 50 µg and Oesclim 25 µg matrix 
patches were cut into eight pieces while Estradot 50 µg small patches were cut in half. 
The cut patches were stored in their respective pouches at +21°C or at +35°C for up to 
1 month. The estradiol drug was extracted from the patch by ethyl acetate n-hexane and 
determined by radioimmunoassay.
Results: Storage at +21°C or +35°C up to 1 month did not reduce the estradiol 
concentration in Estraderm MX, Systen and Oesclim patches. However, although the 
estradiol in Estradot patches was not affected by storage at +21°C, at +35°C, estradiol 
decreased by 57% (±1%) in cut pieces.
Conclusions: Unused Estraderm MX, Systen and Oesclim patch pieces may be stored for at 
least 1 month at ≤+35°C. Where estradiol patches for children are not available, cut pieces 
of these or similar patches can be used for pubertal induction. The Estradot patch was too 
small to properly cut into low doses and not stable in elevated temperatures.
Introduction
Girls with hypogonadism require estrogen replacement 
therapy to induce puberty and maintain secondary sex 
characteristics, as well as to attain peak bone mass. These 
outcomes are achieved by starting with a low estradiol (E2) 
dose, which is then gradually increased for about 3 years 
to an adult estrogen replacement therapy dose. Relatively 
high-dose estrogen replacement therapy at pubertal 
induction may result in rapid and unfavorable breast 
shape development and short stature as an adult, due 
to the accelerated skeletal maturation (1). Accordingly, 
stable and reliable low-dose estrogen replacement therapy 
products are essential for these girls.
The most common example of hypergonadotropic 
hypogonadism is Turner syndrome, resulting from 
gonadal dysgenesis. Most patients fail to enter puberty or 
show pubertal arrest. For the induction of puberty, oral 
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or transdermal E2 may be used. However, the available 
evidence suggests that transdermal administration could 
have a more favorable profile both in cost and efficacy 
than oral estrogen replacement therapy (2, 3). Transdermal 
estrogen replacement therapy has minimal, if any, effect 
on hepatic clotting factor production and other protein 
changes associated with the liver first-pass effect (4, 5). In 
individuals with Turner syndrome, estrogen replacement 
therapy will typically continue for at least 40 years, and 
therefore, should be administered in a route that most 
closely mimics hormone physiology. Consequently, the 
recently published international guideline for Turner 
syndrome recommend transdermal rather than oral E2 
treatment where available (6, 7).
Transdermal E2 patches are primarily designed for 
postmenopausal women. The estimated dose required 
for pubertal induction is one-tenth to one-twentieth of 
the adult dose. Since no commercially available patches 
delivering such small doses, the physician, patient, parent 
or pharmacist has to manipulate formulations intended 
for adult women. This situation is further complicated 
by the need to adjust the dose to mimic the increasing 
E2 serum levels seen during the different stages of 
spontaneous puberty (8). These products are thus used 
not only off-label (i.e. not registered for this use) but also 
non-licensed, as the label does not provide data on the 
manipulated formulation.
Matrix patches consist of a monolayered adhesive 
matrix with uniformly distributed E2. For each formula 
of matrix patch, there is a linear relationship between 
the dose of E2 administered, which is determined by the 
surface area, and serum E2 concentrations. Consequently, 
cutting the E2 patches may be a way of providing lower 
doses. Unfortunately, manufacturers do not recommend 
cutting the E2 patches and claim they cannot guarantee 
uniform distribution of drug throughout the patch, 
despite the fact that this uniformity is a release criterion 
for pharmaceutical batches. This has raised questions from 
pharmacists and led to uncertainty among physicians, 
but the manufacturers have not shown any interest 
(motivation) in evaluating this problem.
Nevertheless, previous studies have shown that by 
cutting the E2 patch into smaller pieces, it is possible to 
provide an individualized dose for pubertal induction 
and thereby mimic hormone physiology (3, 9, 10, 11, 
12, 13, 14). However, members of the Turner Syndrome 
Working Group of the European Society of Paediatric 
Endocrinology (ESPE) consider it important to extend 
current knowledge on the use and storage of whole and 
cut patches for children, particularly to provide data 
that can be applied to different countries with different 
climates.
In this laboratory study, we evaluated four different 
brands of E2 matrix patches from different manufacturers 
to test their feasibility in pubertal induction by testing 
(a) the uniformity of drug E2 distribution on the surface 
area of the patches, (b) the stability of cut patches at 
room temperature (+21°C) and (c) their stability in high 
temperatures (+35°C), representing a hot climate.
Materials and methods
Patches
Four different brands of transdermal E2 patches of 
the matrix type available in Europe were chosen for 
testing: Systen (= Evorel) 50 µg per 24 h (Janssen-Cilag 
International, Beerse, Belgium), Estraderm MX 50 µg per 
24 h (Merus Labs, Amsterdam, Netherlands), Oesclim 
(= Esclim, Esclima) 25 µg per 24 h (Mylan Technologies, 
Canonsburg, PA, USA) and Estradot (= Vivelle dot) 50 µg 
per 24 h (Novartis) (Fig. 1 and Table 1). All patches were 
guaranteed by the manufacturer to have an end-of-
shelf-life content within acceptable margins of the label-
declared concentration until expiry date if stored in the 
A 
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Figure 1
Sketched shapes of four different brands of estradiol matrix patches. (A) 
Systen (= Evorel) 50 µg/24 h; (B) Estraderm MX 50 µg/24 h; (C) Oesclim 
(= Esclim, Esclima) 25 µg/24 h; and (D) Estradot (= Vivelle dot) 50 µg/24 h. 
The estradiol patches are sketched in proportional size to each other. 
Gray lines across the patches in panels A, B and D show the incision for 
opening of the protective liner.
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original protective pouch below +25°C (Systen, Estraderm 
MX, Oesclim) or below +30°C (Estradot). In addition, 
Estradot was labeled ‘Do not store Estradot in refrigerator. 
Keep from freezing’. Therefore, storage in the refrigerator 
was not an option. The patches were stored in the 
original protective pouch and carton at room temperature 
(+21 ± 1°C) until study start. The experiment was carried 
out between October 2017 and March 2018.
Ensuring uniformity of drug distribution and optimal 
E2 extraction procedure
In order to verify the uniform distribution of E2 on the 
surface area of the patches and to determine the optimal 
extraction procedure, a pre-study was performed. The 
patches, backed with a polyester or foiled release liner 
(Fig.  1 and Table  1), were taken out of the foil-lined 
pouches. After removal of the protective release liner, 
each patch was attached to a filter paper (Whatman 903 
for newborn screening; PerkinElmer). Thereafter, patches 
were cut with scissors into between two to eight equal 
pieces, depending on the size and shape of the patch 
(Fig.  2). For Estradot, four patches were used in order 
to obtain eight pieces. Measurement before cutting was 
performed with a ruler. E2 drug concentrations were 
determined in all cut pieces directly without storage.
Stability testing of E2 drug amount in cut patches
Patches of each variety were taken out of the foil-lined 
pouches. Systen, Estraderm MX and Oesclim patches were 
cut with scissors into eight pieces (Fig. 2, panel A, B and C), 
while the small Estradot patches were cut into two pieces 
(Fig. 2D). Patch pieces protected with their polyester or foiled 
release liner were put back into their protective pouches and 
sealed by hand. Half of the pouches were put in airtight plastic 
bags, air pressed and sealed with a zipper (PerkinElmer). The 
patches were stored for up to 1 month, either in a drawer 
Table 1 Description of four brands of E2 matrix patch for potential use in pediatrics.
Systen (= Evorel) Estraderm MX Oesclim (= Esclim, Esclima) Estradot (= Vivelle dot)
Manufacturer Janssen-Cilag International Merus Labs Mylan Technologies Novartis
Dose (µg/24 h) 50 50 25 50
Amount of E2 (mg) 3.2 1.5 5 0.78
Shape and color Square with rounded 
corners, transparent
Square with rounded 
corners, transparent
Rectangular foam 
mounting with rounded 
corners, beige
Rectangular with 
rounded corners, 
transparent
Patch area (cm2) 16 22 11 5
Protective backing A foiled release liner with an 
S-shaped center incision. 
Extending beyond the patch 
with dotted marks along the 
edge
A polyester release 
liner with an incision. 
Extending beyond the 
patch
A polyester release liner 
extending beyond the 
patch, no incision
A polyester release 
liner with an incision. 
The same size as the 
patch
Recommended storage 
conditions
In its protective pouch, 
below +25°C
In its protective 
pouch, below +25°C
In its protective pouch, 
below +25°C
In its protective 
pouch, below +30°C. 
Do not store Estradot 
in refrigerator. Keep 
from freezing
Cmax E2 (pmol/L) with 
50 µg per 24 h patch
184 ± 12 (17) 143 ± 92 (18) 226 ± 121 (19) 201 ± 54 (20)
Cmax E2, average peak plasma E2 concentration determined in postmenopausal women with an average weight of 65 kg; E2, estradiol.
Figure 2
Cutting of estradiol matrix patches. (A) Systen 50 µg/24 h, (B) Estraderm 
MX 50 µg/24 h and (C) Oesclim 25 µg/24 h were cut into eight pieces, while 
(D) Estradot 50 µg/24 h was cut in half. The dashed lines depict how the 
patches were cut in the present study.
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at room temperature, +21°C (± 1°C) or in a heating cabinet 
at +35°C (± 1°C) to represent storage conditions in a hot 
climate. Intact patches in unopened pouches were sealed in 
the same manner (half in airtight plastic bags) and stored 
under the same conditions for comparison and analyzed in 
parallel. During the first 14 days, two pieces of each patch 
variety stored at room temperature were analyzed every third 
to fourth day and thereafter once a week. Estradot patches 
were analyzed once a week. Patch pieces stored at +35°C 
were analyzed after 2 and 4 weeks. The entire experiment 
was performed in duplicate.
Extraction of E2 drug from patch pieces
Each piece of the E2 patches was removed from the 
protective liner and attached to a matched-size filter paper 
(Whatman 903 for newborn screening; PerkinElmer). The 
patch pieces on filter paper were thereafter put in glass tubes 
with a solution of 3.5 mL ethyl acetate/n-hexane (2:3 by 
volume; VWR International AB, Stockholm, Sweden). The 
E2 was extracted from the patch into the solvent by gentle 
vortex for 30 min. The samples were thereafter serially 
diluted (1:176 and 1:76) with ethyl acetate/n-hexane to a 
final volume of 1.5 mL. The organic phase was dried on a 
37°C heat block under a stream of nitrogen and suspended 
in free steroids matrix (MSG3000; Golden West Diagnostics, 
Temecula, CA, USA). After a final dilution 1:16, samples were 
ready for E2 quantification by radioimmunoassay (RIA).
E2 determination
Drug E2 concentrations were determined in duplicate by 
an in-house RIA at the Department of Pediatrics, Göteborg 
Pediatric Growth Research Center in Gothenburg, 
Sweden. Certified reference material was purchased from 
Sigma-Aldrich. A stock calibrator was prepared in absolute 
ethanol and thereafter diluted with MSG3000 blank 
serum to make six calibrators in the range 0–5000 pmol/L. 
Tracer and E2 antibody-coated tubes (ESTR-US-CT) were 
purchased from Cisbio Bioassays (Codolet, France). All 
other reagents were purchased from VWR International 
AB and were of the highest purity available. The lower 
limit of detection was 9 pmol/L. The total coefficient 
of variation (CV) was 9% for 250 pmol/L and above. 
The assay procedure has been described previously and 
validated accordingly (15, 16).
Statistical analyses
Results are presented as median ± range unless stated 
otherwise. The E2 concentration in cut patches (stored at 
+21°C and +35°C in their original pouches versus in an 
airtight plastic bag) are presented as a percentage of the 
E2 content in the original product (intact sealed patches 
stored at +21°C). A deviation of ±20% from the original 
product was considered an acceptable variance.
Results
Validity of the drug extraction procedure and 
uniformity on the patches
The E2 drug amount was adequately extracted from all 
four patches that were tested: 128 ± 7% recovery for 
Systen, 106 ± 14% for Estraderm MX, 126 ± 6% for Oesclim 
and 115 ± 5% for Estradot. The extraction also yielded a 
uniform distribution of E2 drug concentrations on Systen 
(CV between the eight cut pieces was 9%), Estraderm 
MX (CV 10%), Oesclim (CV 11%) and Estradot (CV 13%) 
patch surface areas. This combined result confirmed the 
validity of the study design.
Stability of E2 drug in cut patches at +21°C
Storage at room temperature for up to 1 month did not 
affect the E2 concentration in any of the tested patches. 
All data fell within analytical variability of 4.1 ± 6.4% 
deviation for Systen, 9.1 ± 1.3% for Estraderm MX, 
3.3 ± 2.2% for Oesclim and 6.6 ± 10.0% for Estradot after 
1 month of storage at +21°C, compared to an intact patch 
in an unopened pouch (Fig.  3). Storage in a plastic bag 
yielded similar results (Fig. 3).
Stability of E2 drug in cut patches in the high-
temperature storage condition
Storage at +35°C for up to 1  month did not affect the 
E2 concentration on intact and sealed Systen, Estraderm 
MX and Oesclim patches (Fig.  3, panel A, B and C). In 
addition, the concentration of E2 was stable in cut patches 
with −6.9 ± 6% deviation for Systen, −15.8 ± 1.5% for 
Estraderm MX and −5.0 ± 3.8% for Oesclim after 1 month 
of storage at +35°C, compared to an intact patch in an 
unopened pouch stored at +21°C (Fig. 3, panel A, B and C). 
No difference in E2 concentration was observed between 
storage in a plastic bag or in the pouch only.
However, the E2 drug concentration in the Estradot 
patch deteriorated with storage at +35°C. The E2 decreased 
by 33% (±11%) in intact sealed patches and by 57% (±1%) 
in cut pieces during 1 month of storage (Fig. 3D). Storage 
in airtight plastic bags gave similar results as storage in the 
pouch only.
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Practical experience with using the patches in 
this experiment
Three of the patches, Systen, Estraderm MX and Oesclim, 
were large and easy to cut. They were covered with a 
protective liner that was larger than the patch itself by 
a generous margin (Fig.  1 and Table  1), which was an 
advantage for easy removal and application. Oesclim 
was a thicker patch compared to the others, rectangular 
in shape and very easy to cut and handle. Square-shaped 
patches with rounded corners were easier to cut into 
equal wedges than into perfect rectangles (Fig. 2). For the 
purposes of this study, we cut the patches to a practical 
size that would ensure accuracy. These patches adhered 
well on the filter paper after cutting and storage.
The Estradot patch was a miniature rectangular 
patch, which was too small to be properly cut into small 
pieces. Smaller pieces than 1/8 of a 50 µg patch (0.6 cm2) 
were extremely difficult to handle. The protective liner 
had no extra space surrounding the patch itself (Fig. 1), 
and it was therefore difficult to remove the protective 
liner from the patch when cut into small pieces. Only 
the pieces surrounding the incision could easily be 
separated from the protective liner. The substance of the 
content on the Estradot patch surface was thicker and 
more glutinous compared to the other brands. When 
the Estradot patch was cut with scissors, a small amount 
of this content leaked out. However, the patch adhered 
well on the filter paper after cutting and storage. In the 
extraction procedure, the drug contents turned gray in 
the solvent phase, which did not occur with the other 
three products.
Discussion
This is the first report on the utility and stability of E2 
matrix patches in cut pieces as well as the impact of storage 
in higher temperatures. This study showed that the E2 
drug amount was uniformly distributed over the tested 
E2 matrix patches Systen, Estraderm MX and Oesclim, 
and we therefore consider it safe to cut these patches into 
smaller pieces. In addition, we have demonstrated that the 
cut patches can be safely stored in their original protective 
pouches for up to 1 month at +35°C. The Estradot patch 
is very small and can be safely cut in half; however, it did 
not meet our stability criteria.
Pediatricians will, in general, prefer to use registered 
and licensed products. Nevertheless, in the absence 
of very-low-dose E2 patches, cutting patches of one of 
the three studied brands Systen, Estraderm MX and 
Oesclim will reliably deliver the correct dose when used 
directly after cutting into pieces or after storage of up to 
1 month. This study indicates that E2 matrix patches with 
similar size and shape will behave in the same manner. 
Consequently, we expect that more pediatricians 
in different countries with different climates will 
be encouraged to choose transdermal E2 treatment 
Figure 3
Evaluation of stability of four different E2 matrix 
patches. (A) Systen (= Evorel); (B) Estraderm MX; 
(C) Oesclim (= Esclim, Esclima); and (D) Estradot 
(= Vivelle dot). Patches were cut into pieces and 
stored either at +21 ± 1°C (gray lines) or at 
+35 ± 1°C (black lines) for up to 1 month. Half of 
the tested patches were stored in the original 
pouch (square symbols) and the other half in the 
pouch inside a small sealed airtight plastic bag 
(circle symbols). Filled symbols depict patches 
stored intact and sealed for 30 days at +35°C. 
Results are presented as median difference in E2 
drug concentrations ± range compared to an 
intact patch that had been stored sealed in its 
original pouch at +21°C until cut and analyzed in 
parallel. E2, estradiol.
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according to the guidelines for girls with hypogonadism 
(6, 7). Traveling with patches will not be an issue as those 
patches were found to be relatively resistant to higher 
temperatures. However, controlled trials are still needed 
in order to determine which regimen provides the best 
clinical outcomes. This study brings us one step closer to 
future clinical studies involving cut pieces of transdermal 
E2 matrix patches.
Three of the patches, Systen, Estraderm MX and 
Oesclim, were relatively large and covered with a generously 
sized protective liner which made them easy to cut. In this 
study, the patches were cut into eight pieces for practical 
reasons. Nonetheless, cutting into sixteen pieces is possible 
and has been used in clinical practice (12); this would not 
have changed the results in this experimental study. In 
daily practice, precise cutting is not crucial as long as a 
larger patch is cut with ±1 mm error, but, particularly for 
the convenience and safety of the youngest patients using 
a very low dose, it would be preferable if the pharmacist 
cut the patch to ensure precision.
The least stable patch was the Estradot patch. This 
miniature E2 patch is cosmetically preferable for adult 
women, but it was too small to properly cut into small 
pieces. Like the Systen and Estraderm MX patch, it was 
designed to deliver 50 µg per 24 h, but with a lower drug 
E2 concentration (0.78 mg), on a surface area that was just 
one-quarter to one-third of the surface area of those two 
brands. We assume that in order to obtain the same delivery 
criteria on a small area, the content on the Estradot patch 
surface was thicker compared to the others. In practice, 
the Estradot patch may be cut into 6 µg (0.6 cm2) pieces, 
that is 1/8 of a 50 µg patch or 1/4 of a 25 µg patch. Smaller 
pieces were impractical to handle, and cutting such small 
patches would be prone to inaccuracies. Only the pieces 
surrounding the incision could easily be removed from 
the release liner, which leads us to suspect that users in 
many cases have to discard the unusable patch fractions. 
Nonetheless, it seems that some users manage to cut even 
smaller pieces (11).
We favor physiologically administered estrogen 
replacement therapy, in other words, mimicking the 
diurnal variation of E2 seen in early puberty by nocturnal 
application of a cut piece (approximately 3 µg) of an 
E2 patch (9, 12). For this reason, the Estradot patch is 
not applicable for pubertal induction in the youngest 
girls with the lowest weight. We recommend using the 
Estradot E2 patch only in older girls who weigh more, 
since the proposed regimen of starting with a 6 µg patch 
piece and applying it for 3–4 days per week (3) has not 
been evaluated clinically. Another consideration is that 
the Estradot E2 patch is unstable both in the fridge 
(according to the manufacturer’s information) and in 
hot temperatures (in our experiment), which limits its 
utility in some climates.
The patches tested in this study were comparable 
in terms of E2 delivery into the blood, indicating no 
difference in serum or plasma E2 concentrations (about 
200 pmol/L) with 50 µg E2 patches in postmenopausal 
women (17, 18, 19, 20). The inter-individual variation 
has been reported to be less with transdermal E2 patches 
(three-fold) compared to transdermal gel (seven-fold) 
(21). Although only four brands of E2 matrix patches 
were tested in this study, we assume that the results are 
applicable to other similar E2 matrix patches.
One limitation of this study is that the effect of 
humidity was not tested. Although the absence of 
guidance from the manufacturer suggests that humidity 
is not an issue for storage, we do not rule out the 
possibility of an effect. On the other hand, E2 is only 
slightly soluble in water, and we therefore believe that 
humidity will have little impact on stability. Until this is 
established, we recommend using an airtight plastic bag 
in order to avoid any effect of humidity during storage. 
This study yielded no difference in stability with or 
without a plastic bag. All cut patches adhered well on 
the filter paper after storage for up to 1 month. Although 
we did not test the cut patches on skin, we assume that 
the adhesive quality would not differ.
Conclusions
The drug amount was uniformly distributed over the 
surface area of the tested Estraderm MX, Oesclim, Systen 
and Estradot E2 matrix patches, and we therefore consider 
it safe to cut the patches into smaller pieces. The Estraderm 
MX, Oesclim and Systen E2 patches are large enough to 
easily be cut into small pieces, in order to achieve very 
low E2 doses. Unused patch pieces were stable for at least 
1 month in the original protective pouch at up to +35°C. 
Since E2 patches for children are not available, cut pieces 
of these three brands of E2 matrix patch can be used to 
induce puberty in hypogonadal girls. The Estradot E2 
patch, however, was too tiny to properly cut into small 
pieces for pubertal induction and not stable for storage in 
a hot climate.
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